Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

NCT05387239 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor request

Conditions

Pulmonary Fibrosis
COVID-19 Respiratory Infection

Interventions

DRUG: VL-PX10 and VL-P22 plus standard care
DRUG: Placebo

Sponsor

Vitti Labs, LLC